Derivatives and Quantitative Strategist

Gaudenz Schneider

Equity Bottom-Up

<ul>
<li>
Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.</li>
<li>
Highlights: Currently 19 pair trade opportunities persist across four markets and eight sectors.
</li>
<li>
Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.</li>
</ul>



Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.

Highlights: Currently 19 pair trade opportunities persist across four markets and eight sectors.


Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.


Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (1 June 2026)

<ul>
<li>
Context: Following F&amp;P earnings, The Fisher &amp; Paykel Health (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlight: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed Inc (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a>  targets a 8% return.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: Following F&amp;P earnings, The Fisher &amp; Paykel Health (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlight: Going long ResMed Inc (RMD AU) and short Fisher &amp; Paykel Healthcare (FPH AU)  targets a 8% return.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU) Vs. F&P Health (FPH AU): Earnings Jump Triggers Stat Arb Signal

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>ResMed, Inc. reported its third quarter results for fiscal year 2026, delivering solid financial and operational performance marked by 11% headline revenue growth and 8% growth on a constant currency basis.</li><li>The company highlighted a significant 21% increase in non-GAAP earnings per share, supported by operating leverage and margin expansion.</li><li>Gross margin expanded by 290 basis points year-over-year and 50 basis points sequentially, driven by component cost improvements, manufacturing and logistics efficiencies, as well as favorable product mix and currency effects.</li></ul>

ResMed, Inc. reported its third quarter results for fiscal year 2026, delivering solid financial and operational performance marked by 11% headline revenue growth and 8% growth on a constant currency basis.The company highlighted a significant 21% increase in non-GAAP earnings per share, supported by operating leverage and margin expansion.Gross margin expanded by 290 basis points year-over-year and 50 basis points sequentially, driven by component cost improvements, manufacturing and logistics efficiencies, as well as favorable product mix and currency effects.

ResMed: Why Restless Legs Syndrome, Sleep Apnea Testing & Digital Platforms Matter Now!

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare Cor (FPH AU)</a> targets a 6% return.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Health (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long ResMed (RMD AU) and short Fisher &amp; Paykel Healthcare Cor (FPH AU) targets a 6% return.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> targets a 5% return, with ResMed supported by cheaper valuations.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Healthcare (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long ResMed (RMD AU) and short Fisher &amp; Paykel Healthcare (FPH AU) targets a 5% return, with ResMed supported by cheaper valuations.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ResMed Inc (RMD AU)

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (1 June 2026)

Discover 19 pair trade opportunities across four markets and eight sectors using statistical mean-reversion methodology for actionable insights.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Earnings Jump Triggers Stat Arb Signal

8% target return in a potential pair trade after Fisher & Paykel Health’s earnings jump pushed the healthcare spread beyond a two-standard...

Gaudenz Schneider

ResMed: Why Restless Legs Syndrome, Sleep Apnea Testing & Digital Platforms Matter Now!

ResMed, Inc. reported its third quarter results for fiscal year 2026, delivering solid financial and operational performance marked by 11%...

Baptista Research

ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

Relative value opportunity targeting a 6% return as the healthcare spread diverges again in a pair trade with a strong track record. Ideal for...

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...

Gaudenz Schneider

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (1 June 2026)

​Discover 19 pair trade opportunities across four markets and eight sectors using statistical mean-reversion methodology for actionable insights.

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Earnings Jump Triggers Stat Arb Signal

8% target return in a potential pair trade after Fisher & Paykel Health’s earnings jump pushed the healthcare spread beyond a two-standard...

Gaudenz Schneider

ResMed: Why Restless Legs Syndrome, Sleep Apnea Testing & Digital Platforms Matter Now!

ResMed, Inc. reported its third quarter results for fiscal year 2026, delivering solid financial and operational performance marked by 11%...

Baptista Research

ResMed (RMD AU) Vs. F&P Health (FPH AU): Recurring Stat Arb Opportunity Targets 6 Percent

Relative value opportunity targeting a 6% return as the healthcare spread diverges again in a pair trade with a strong track record. Ideal for...

Gaudenz Schneider

ResMed (RMD AU) Vs. F&P Health (FPH AU): Proven Statistical Arbitrage Pair Trade Returns

​Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...

Gaudenz Schneider

Discover 19 pair trade opportunities across four markets and eight sectors using statistical mean-reversion methodology for actionable insights.

Targeting 5%, the dislocation of the two stock's price ratio presents a potential relative value opportunity for traders seeking mean-reversion...